# The Swedish BioFINDER 2 Study

> **NCT03174938** · NA · RECRUITING · sponsor: **Skane University Hospital** · enrollment: 2950 (estimated)

## Conditions studied

- Dementia
- Alzheimer Disease
- Parkinson Disease
- Lewy Body Disease
- Parkinson-Dementia Syndrome
- Frontotemporal Degeneration
- Semantic Dementia
- Progressive Nonfluent Aphasia
- Progressive Supranuclear Palsy
- Corticobasal Degeneration
- Multiple System Atrophy
- Mild Cognitive Impairment
- ALS (Amyotrophic Lateral Sclerosis)

## Interventions

- **DIAGNOSTIC_TEST:** Flutemetamol F18 Injection
- **DIAGNOSTIC_TEST:** [18F]-RO6958948
- **DIAGNOSTIC_TEST:** Elecsys (Roche) Abeta42, Ttau and Ptau
- **DIAGNOSTIC_TEST:** Lumipulse (Fujirebio) Abeta42, Ttau and Ptau

## Key facts

- **NCT ID:** NCT03174938
- **Lead sponsor:** Skane University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-05-15
- **Primary completion:** 2036-12
- **Final completion:** 2036-12
- **Target enrollment:** 2950 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03174938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03174938, "The Swedish BioFINDER 2 Study". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03174938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*